Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Reports Q4 2023 Financial Results
Summary
Regeneron Pharmaceuticals, Inc. reported its financial results for the fourth quarter and full year of 2023, showing an 8% increase in full-year revenues to $13.12 billion and a 31% increase in Dupixent global net sales to $11.59 billion. The company's total net product sales grew by 1% to $3.43 billion in Q4 2023, and net income decreased by 3% to $1.16 billion. Regeneron also provided financial guidance for 2024, projecting GAAP R&D expenses between $4.820 billion and $5.070 billion and GAAP SG&A expenses between $2.890 billion and $3.090 billion.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement